The stock price of Capricorn Therapeutics fell 48.5% after a panel of experts from the US Food and Drug Administration voted to reject the company's treatment for heart disease caused by Duchenne muscular dystrophy.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.